MedTrace Logo

Fast Advanced Closed-Loop Therapy

NCT04853030 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-10-01

No results posted yet for this study

Summary

A double-blind, multinational, multicenter, randomised, 2-period crossover study to assess the efficacy and safety of advanced closed-loop insulin delivery with Minimed 670G 4.0 system comparing Faster Insulin Aspart to Standard Insulin Aspart therapy over 4 weeks in active children and adolescents with type 1 diabetes.

Conditions

Interventions

DRUG

Fiasp

Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)

DRUG

Novorapid

Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid

Sponsors & Collaborators

  • Medical University of Graz Department of Pediatrics and Adolescent Medicine, Graz, Austria

    collaborator UNKNOWN

  • UMC Ljubljana University Children's Hospital Ljubljana

    collaborator UNKNOWN

  • University of Ljubljana, Faculty of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-06
Primary Completion
2021-09-16
Completion
2021-09-20

Countries

  • Austria
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853030 on ClinicalTrials.gov